Literature DB >> 20432458

Regulation of adult bone turnover by sex steroids.

Baruch Frenkel1, Albert Hong, Sanjeev K Baniwal, Gerhard A Coetzee, Claes Ohlsson, Omar Khalid, Yankel Gabet.   

Abstract

Recent reports reveal increasing complexity of mechanisms underlying the bone sparing effects of sex steroids. This review focuses on mechanisms by which sex steroids attenuate endocortical and trabecular adult bone turnover, perhaps their most important property as bone mass regulators. Clearly, estrogen withdrawal increases osteoclast number and bone resorption; however, important open questions are the extent to which osteoblasts and their precursors are involved, and the relative contributions of the RANK/RANKL/OPG system, Fas ligand and Runx2. In addition to reviewing these aspects of estrogen action, we also discuss proskeletal effects of androgens on the adult male skeleton, including aromatization to estrogens and male-specific mechanisms. Detailed understanding of skeletal site- and gender-dependent mechanisms by which sex steroids protect the adult skeleton will provide the foundation for improved risk assessment, prevention and management of osteoporosis.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20432458      PMCID: PMC5770230          DOI: 10.1002/jcp.22159

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  64 in total

1.  Increased production of IL-7 uncouples bone formation from bone resorption during estrogen deficiency.

Authors:  M Neale Weitzmann; Cristiana Roggia; Gianluca Toraldo; Louise Weitzmann; Roberto Pacifici
Journal:  J Clin Invest       Date:  2002-12       Impact factor: 14.808

2.  Androgens, estrogens, and bone turnover in men.

Authors:  Sundeep Khosla; B L Riggs
Journal:  J Clin Endocrinol Metab       Date:  2003-05       Impact factor: 5.958

3.  Increased bone mass as a result of estrogen therapy in a man with aromatase deficiency.

Authors:  J P Bilezikian; A Morishima; J Bell; M M Grumbach
Journal:  N Engl J Med       Date:  1998-08-27       Impact factor: 91.245

4.  Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts.

Authors:  T Komori; H Yagi; S Nomura; A Yamaguchi; K Sasaki; K Deguchi; Y Shimizu; R T Bronson; Y H Gao; M Inada; M Sato; R Okamoto; Y Kitamura; S Yoshiki; T Kishimoto
Journal:  Cell       Date:  1997-05-30       Impact factor: 41.582

5.  Sex- and age-related response to aromatase deficiency in bone.

Authors:  C Miyaura; K Toda; M Inada; T Ohshiba; C Matsumoto; T Okada; M Ito; Y Shizuta; A Ito
Journal:  Biochem Biophys Res Commun       Date:  2001-02-02       Impact factor: 3.575

6.  Bone has a sexually dimorphic response to aromatase deficiency.

Authors:  O K Oz; J E Zerwekh; C Fisher; K Graves; L Nanu; R Millsaps; E R Simpson
Journal:  J Bone Miner Res       Date:  2000-03       Impact factor: 6.741

Review 7.  Aromatase activity and bone homeostasis in men.

Authors:  Luigi Gennari; Ranuccio Nuti; John P Bilezikian
Journal:  J Clin Endocrinol Metab       Date:  2004-12       Impact factor: 5.958

8.  Estrogen prevents bone loss via estrogen receptor alpha and induction of Fas ligand in osteoclasts.

Authors:  Takashi Nakamura; Yuuki Imai; Takahiro Matsumoto; Shingo Sato; Kazusane Takeuchi; Katsuhide Igarashi; Yoshifumi Harada; Yoshiaki Azuma; Andree Krust; Yoko Yamamoto; Hiroshi Nishina; Shu Takeda; Hiroshi Takayanagi; Daniel Metzger; Jun Kanno; Kunio Takaoka; T John Martin; Pierre Chambon; Shigeaki Kato
Journal:  Cell       Date:  2007-09-07       Impact factor: 41.582

9.  Estrogen protects bone by inducing Fas ligand in osteoblasts to regulate osteoclast survival.

Authors:  Susan A Krum; Gustavo A Miranda-Carboni; Peter V Hauschka; Jason S Carroll; Timothy F Lane; Leonard P Freedman; Myles Brown
Journal:  EMBO J       Date:  2008-01-24       Impact factor: 11.598

10.  Overexpression of Cbfa1 in osteoblasts inhibits osteoblast maturation and causes osteopenia with multiple fractures.

Authors:  W Liu; S Toyosawa; T Furuichi; N Kanatani; C Yoshida; Y Liu; M Himeno; S Narai; A Yamaguchi; T Komori
Journal:  J Cell Biol       Date:  2001-10-01       Impact factor: 10.539

View more
  52 in total

Review 1.  Inflammatory bone loss: pathogenesis and therapeutic intervention.

Authors:  Kurt Redlich; Josef S Smolen
Journal:  Nat Rev Drug Discov       Date:  2012-03-01       Impact factor: 84.694

2.  Follistatin-like 3 is a mediator of exercise-driven bone formation and strengthening.

Authors:  J Nam; P Perera; R Gordon; Y H Jeong; A D Blazek; D G Kim; B C Tee; Z Sun; T D Eubank; Y Zhao; B Lablebecioglu; S Liu; A Litsky; N L Weisleder; B S Lee; T Butterfield; A L Schneyer; S Agarwal
Journal:  Bone       Date:  2015-04-30       Impact factor: 4.398

3.  Increased PTHrP and decreased estrogens alter bone turnover but do not reproduce the full effects of lactation on the skeleton.

Authors:  Laleh Ardeshirpour; Susan Brian; Pamela Dann; Joshua VanHouten; John Wysolmerski
Journal:  Endocrinology       Date:  2010-11-03       Impact factor: 4.736

4.  Runx2 promotes both osteoblastogenesis and novel osteoclastogenic signals in ST2 mesenchymal progenitor cells.

Authors:  S K Baniwal; P K Shah; Y Shi; J H Haduong; Y A Declerck; Y Gabet; B Frenkel
Journal:  Osteoporos Int       Date:  2011-09-01       Impact factor: 4.507

5.  Sex hormone-binding globulin (SHBG) as an independent determinant of bone mineral density (BMD) among Chinese middle-aged and elderly men.

Authors:  Xiao-Yun Zha; Yu Hu; Xiao-Na Pang; Ji-Heng Zhu; Gui-Lin Chang; Li Li
Journal:  Endocrine       Date:  2014-01-10       Impact factor: 3.633

Review 6.  Circulating monocytes: an appropriate model for bone-related study.

Authors:  Y Zhou; H-W Deng; H Shen
Journal:  Osteoporos Int       Date:  2015-07-21       Impact factor: 4.507

Review 7.  The association between critical illness and changes in bone turnover in adults: a systematic review.

Authors:  N Orford; C Cattigan; S L Brennan; M Kotowicz; J Pasco; D J Cooper
Journal:  Osteoporos Int       Date:  2014-05-07       Impact factor: 4.507

8.  Clinical characteristics and bisphosphonates treatment of rare pregnancy- and lactation-associated osteoporosis.

Authors:  Lu-Jiao Li; Jia Zhang; Peng Gao; Fang Lv; Yu-Wen Song; Xiao-Yan Chang; Di-Chen Zhao; Ou Wang; Yan Jiang; Xiao-Ping Xing; Wei-Bo Xia; Mei Li
Journal:  Clin Rheumatol       Date:  2018-06-26       Impact factor: 2.980

9.  The microenvironment matters: estrogen deficiency fuels cancer bone metastases.

Authors:  Laura E Wright; Theresa A Guise
Journal:  Clin Cancer Res       Date:  2014-05-06       Impact factor: 12.531

Review 10.  AES/GRG5: more than just a dominant-negative TLE/GRG family member.

Authors:  Brandon Beagle; Gail V W Johnson
Journal:  Dev Dyn       Date:  2010-11       Impact factor: 3.780

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.